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Abstract
Background: Peroxynitrite was hypothesized to be
involved in the pathogenesis of multiple sclerosis
(MS) through its various neurotoxic effects. Uric acid
(UA) was shown to be a strong peroxynitrite
scavenger.
Methods: We analyzed cerebrospinal fluid (CSF) and
serum UA concentrations in 30 MS patients and 20
controls with non-inflammatory neurological diseases
(NIND) and correlated these findings with demo-
graphic and clinical characteristics of MS patients.
Disease activity was assessed by brain magnetic res-
onance imaging (MRI) and the CSF/serum albumin
quotient as an indicator of the state of blood-brain-
barrier (BBB).
Results: Serum UA concentrations were found to be
significantly lower in MS patients compared with
controls (ps0.019). CSF UA concentrations were low-
er in MS patients as compared to controls, as well as
in patients with active MS (clinical and/or MRI activity)
in comparison to patients with inactive MS or con-
trols, but these differences were not statistically sig-
nificant. Significant correlation was found between
CSF and serum UA concentrations (ps0.016) in MS
patients, but not in controls; and between CSF UA
concentrations and the CSF/serum albumin quotient
in MS patients (ps0.043), but not in controls.
Conclusions: Our results support the significance of
UA in the pathogenesis of MS. Decreased serum
UA concentrations in MS patients might be due to
both intrinsically reduced antioxidant capacity and
increased UA consumption in MS. CSF UA concentra-
tions may not be a reliable marker of disease activity
in MS since its concentration is dependent on leakage
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of UA molecules from serum through the damaged
BBB and the balance between consumption/produc-
tion within the central nervous system (CNS).
Clin Chem Lab Med 2009;47:848–53.
Keywords: cerebrospinal fluid (CSF); disease activity;
multiple sclerosis (MS); serum; uric acid (UA).
Introduction
Multiple sclerosis (MS) is a chronic inflammatory and
demyelinating disease of the central nervous system
(CNS) (1). In the wide variety of immune-mediated
mechanisms and molecules that could potentially
cause CNS tissue damage in MS, many results point
to the pathogenetic significance of nitric oxide (NO)
(2–4). Several studies have shown that NO is pro-
duced in excess in the CNS (5–7) and NO metabolites
are increased in body fluids of patients with MS
(8–10). The toxicity of NO is significantly enhanced
when it combines with superoxide to rapidly form
the peroxynitrite anion (11). Peroxynitrite has been
shown to be one of the most damaging free radicals
and may exert its toxic effects directly, or by reducing
the total antioxidant capacity through the number of
mechanisms (12–14).
It has been shown that uric acid (UA) can scavenge
not only peroxynitrite, but other free radicals (15, 16).
UA is the final product of purine metabolism and
accounts for ;60% free radical scavenging activity in
human blood (15). In a mouse model of MS, experi-
mental autoimmune encephalomyelitis (EAE), the
administration of exogenous UA was shown to pre-
vent or suppress CNS tissue damage and clinical
manifestations of the disease (17–19). Protective
effects of UA on the blood-CNS barrier in EAE have
been also demonstrated (20). Significantly lower
serum UA concentrations were found in MS patients
compared to controls in some studies (21–23), and
low serum UA concentrations have been suggested
to be a potential marker of disease activity in some
MS patients (24).
In healthy subjects, CSF UA concentrations are 10
times lower compared with serum (25), and serum UA
molecules can leak through the damaged blood-brain-
barrier (BBB) (26). Available data on CSF UA concen-
trations in MS patients is scarce and controversial.
Previous studies show CSF UA concentrations in MS
patients to be either increased (27), the same as in
control patients (28), or reduced in MS patients com-
pared with controls (29). Only one study has investi-
gated CSF UA concentrations in relation to disease
activity (28).
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Figure 1 Concentration of uric acid in serum and cerebro-
spinal fluid from patients with multiple sclerosis, and con-
trols with non-inflammatory neurological disorders.
MS, multiple sclerosis; CSF, cerebrospinal fluid. Bars repre-
sent means with standard deviation.
The aim of our study was to analyze CSF and serum
UA concentrations in patients with MS and control
patients, and to correlate these findings with demo-
graphic (gender, age), clinical (disease duration, dis-
ease course, neurological disability level, clinical
disease activity) and paraclinical parameters (brain
magnetic resonance imaging (MRI) activity, CSF/
serum albumin quotient).
Materials and methods
Blood and CSF samples were collected from 30 consecutive
MS patients who were hospitalized at the Institute of Neu-
rology, Clinical Center of Serbia, Belgrade, for diagnostic or
therapeutic purposes. The diagnosis of MS was established
according to the criteria of McDonald et al. (30). There were
21 females and nine males (M/F 1:2.5); mean age was
38.7 years (SD, 8.9; range 22–53 years), the mean duration
of disease was 6.0 years (SD, 6.1; range 0.5–21 years). Neu-
rological disability was assessed using the expanded disa-
bility status scale (EDSS) (31). The median EDSS score in our
patients was 4.5 (range, 1.0–8.0). Twenty-four patients had
the relapsing-remitting (RR) form of the disease (80%), three
had secondary progressive (SP) (10%) and three patients had
primary progressive (PP) MS (10%).
Fourteen patients in the RR patients group were in exac-
erbation, the remaining 10 were in remission. Exacerbation
was defined according to the criteria of McDonald et al. (30).
Collection of CSF and blood occurred during a two-week
period following the onset of an exacerbation. Patients with
progressive MS were considered to have clinically active dis-
ease when the EDSS score increased by at least one point
from the previous year. Thus, two SP MS patients and three
with PP disease were considered to have clinically active MS.
Additionally, all patients had brain MRI scans with gado-
pentetate dimeglumine (Gd-DTPA) injection performed the
same day that blood and CSF were collected. MRI of the
head was performed using a Siemens Magnetom (1.0 Tesla,
Erlangen, Germany). The scanning protocol included T2-
weighted spin-echo images (TRs4000 ms; TEs90 ms) and
T1-weighted spin-echo images (TRs560 ms; TEs15 ms), in
the transverse plane, with a 5 mm slice thickness. Gd-DPTA
was given intravenously at a dose of 0.1 mmol/kg. Approx-
imately 15 min after contrast injection, T1-weighted se-
quence was repeated. The same experienced neuroradiologist
determined the presence of Gd-DTPA-enhancing lesions.
The presence of at least one Gd-DTPA-enhancing lesion on
the brain MRI served as a marker of MRI activity. Active
lesions were found in 10 RRMS patients (one in remission
and nine with exacerbation of RRMS).
According to the clinical and MRI criteria of disease activ-
ity, 20 patients were judged to have active MS (clinical and/
or MRI activity). Out of these 20 patients, 15 were with RRMS
(14 patients with clinical exacerbation and one with clinically
stable disease but with an active lesion on brain MRI). Two
patients had SPMS and three had PPMS. The remaining 10
patients (nine with RR and one with SP disease) had inactive
MS.
A group of 20 age- and sex-matched patients with other
non-inflammatory neurological diseases (NIND): epilepsy
(ns6), lumbar disc herniation (ns11), pseudotumor cerebri
(ns3), served as controls.
All MS patients and controls gave informed consent prior
to participation in the study and the study was approved by
the Local Ethics Committee. Excluded from the study were
patients with chronic renal disease and diabetes mellitus, as
well as those receiving acetylsalicylic acid, thiazide diuretics,
steroids or other drugs which have been reported to mod-
ulate serum UA levels (32). None of the patients suffered
from gout. Since diet can influence serum uric concentration
based on its purine content, all patients received the same
diet in the hospital for 7 days prior to blood/CSF sampling.
Lumbar puncture and blood collection were performed
simultaneously in all patients after an overnight fast. Ali-
quots were immediately frozen at –208C. UA concentrations
in sera and CSF were determined using a commercially
available enzymatic colorimetric assay according to the
manufacturer’s instructions (Randox-analyzer Monarch,
Milan, Italy). In our institution, the normal range for serum
UA is 140–400 mmol/L for females and 200–460 mmol/L for
males.
Serum and the CSF albumin concentrations were deter-
mined using a commercially available nephelometric meth-
od according to the manufacturer’s instructions (Behring,
Marburg, Germany). The CSF/serum albumin quotient was
used as an indicator of the integrity of the BBB.
The Mann-Whitney U-test was used for comparisons
between groups. Spearman’s rank correlation test was used
to assess correlations.
Results
We analyzed CSF and serum UA concentrations in 30
MS patients and 20 NIND controls (Figure 1). Mean
serum UA concentrations were significantly lower in
MS patients (267.2"70.2 mmol/L; range, 110–407
mmol/L), compared with controls (294.5"55.13
mmol/L; range, 199–400 mmol/L) (ps0.019). Mean
CSF UA concentrations were lower in MS patients
(29.8"12.3 mmol/L; range, 2–55 mmol/L) compared
with NIND controls (35.2"14.0 mmol/L; range,
19–72 mmol/L). However, this difference did not reach
statistical significance (ps0.082).
In patients with active MS, mean UA concentrations
were lower in both the CSF (28.5"13.7 mmol/L; range,
2–53 mmol/L) and serum (262.65"75.3 mmol/L; range,
110–407 mmol/L) compared with patients with inac-
tive MS, in whom the mean value of CSF UA was
33.1"11.7 mmol/L (range, 12–55 mmol/L) and the
mean serum UA was 281.7"60.0 mmol/L (range,
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Table 1 Concentration of uric acid in cerebrospinal fluid of patients with various clinical phenotypes of multiple sclerosis.
Patients Levels of uric acid in the cerebrospinal fluid, mmol/L
Disease course No. Mean"SD Median Range
RRMSa 24 29.1"13.2 28.5 2.0–55.0
Relapse 14 26.5"13.4 24.0 2.0–53.0
Remission 10 33.4"12.4 35.0 12.0–55.0
SPMSb 3 23.7"9.2 28.0 13.0–30.0
Active 2 20.5"10.6 20.5 13.0–28.0
Inactive 1 30.0 – –
PPMSc 3 40.7"12.5 41.0 28.0–53.0
Active 3 40.7"12.5 41.0 28.0–53.0
Inactive 0 – – –
Total 30 29.8"12.3 28.5 2.0–55.0
aRRMS, relapsing-remitting multiple sclerosis; bSPMS, secondary-progressive multiple sclerosis; cPPMS, primary-progressive
multiple sclerosis.
Figure 2 Comparison of the concentration of uric acid in
cerebrospinal fluid from patients with active MS, inactive
MS, and controls with non-inflammatory neurological
disorders.
UA, uric acid; MS, multiple sclerosis; CSF, cerebrospinal
fluid. Bars represent means with standard deviation.
200–373 mmol/L). However, this difference was not
statistically significant (ps0.271, and ps0.489,
respectively).
As shown in Figure 2, a trend toward a statistically
significant difference between patients with active MS
and controls was observed only in the mean CSF UA
concentrations (ps0.09) (Figure 2).
We found significant correlation between CSF and
serum UA concentrations in patients with MS
(rs0.462, ps0.016). No correlation was found in
NIND controls (rs0.235, ps0.315).
CSF UA concentrations were highest in patients
with the PP form of MS. Statistical comparisons
regarding patients with PPMS (ns3) and SPMS (ns3)
were not performed due to the small number of
patients with progressive forms of the disease. CSF
UA concentrations did not differ significantly between
patients with RRMS and those with progressive forms
of the disease (SPMSqPPMS) (ps0.406) (Table 1).
We did not find statistically significant differences
between mean CSF UA concentrations in patients
with RRMS vs. NIND controls (ps0.186), and between
patients with RRMS in relapse vs. patients with RRMS
but in remission (ps0.189).
No significant correlation was found between CSF
UA concentrations and age of MS patients (rs–0.20,
ps0.916), duration of disease (rs–0.030, ps0.873) or
degree of neurological disability as assessed by the
EDSS score (rs–0.282, ps0.131). However, signifi-
cant correlation was found between CSF UA concen-
trations and female gender in MS patients (rs–0.613,
ps0.0001).
Significant correlation was also found between CSF
UA concentrations and the CSF/serum albumin quo-
tient (data not shown) in MS patients (rs0.511,
ps0.043), but not in controls (rs–0.102, ps0.794).
Discussion
In our investigation, we found significantly lower
serum UA concentrations in MS patients compared
with NIND controls, and slightly lower, but not statis-
tically significant, CSF UA concentrations in MS
patients compared with NIND controls. Similarly, in
patients with active MS, the mean UA concentration
was lower both in the CSF and serum compared with
patients with inactive MS. However, the difference
between serum and CSF for the two MS patient
groups was not statistically significant. We did
observe a trend toward statistical significance for
mean CSF UA concentrations in patients with active
MS vs. controls. It is possible that this difference
might be statistically significant if a larger patient
group was studied.
In a study of 34 MS patients and 20 controls with
NIND, Stover et al. found 2–3-fold increases in CSF
UA concentrations in MS patients compared with con-
trols (27). Additionally, Becker et al. found normal UA
concentrations in blood and CSF of 18 patients with
MS (33). In a recent study by Zamani et al. (29), CSF
and serum UA concentrations were measured in 12
patients with MS and 10 controls. Both CSF and
serum UA concentrations were significantly less in
MS patients compared with controls. However, in
the above-mentioned studies, there are no data
on clinical or brain MRI activity. A study by
Kastenbauer et al. (28) investigated CSF UA concen-
trations in relation to disease activity. However, this
study did not show any significant difference in serum
and CSF UA concentrations between MS patients,
with both active or inactive disease, and controls. The
authors speculated that the patient selection for the
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control group could have influenced the results of this
study (28).
Whether the reduction of UA concentrations in
patients with active MS, as found in some studies
(21, 29), is a cause or a consequence of disease activ-
ity remains unclear. It may be speculated that patients
with active MS may have intrinsically reduced anti-
oxidant capacity, which contributes to the tissue dam-
age in MS. Epidemiological studies have found MS
and gout, characterized by increased UA concentra-
tions in serum, are mutually exclusive (17). Studies in
twins showed that siblings with MS had lower serum
UA concentrations compared with the healthy individ-
ual (22). Additionally, lower serum UA concentrations
have been found in patients with optic neuritis (34),
and in patients with other forms of the clinically iso-
lated syndrome (CIS) (23). In accordance with these
findings, we have previously demonstrated signifi-
cantly lower mean serum UA concentrations in MS
patients compared with NIND controls (21). Female
gender correlated inversely with both serum UA con-
centrations in our previous study (21), and with CSF
UA concentrations in this study. Thus, it could be
presumed that the reduced antioxidant capacity, as
assessed by the lower CSF UA concentrations in
female patients with MS, could partially explain the
predominance of females with MS. On the other
hand, CNS inflammation in the active phase of the
disease could lead to the consumption of UA and a
reduction of the UA scavenger activity. In our previ-
ous study of 240 patients with MS, we found signifi-
cantly lower serum UA concentrations in patients
with clinical symptoms and/or MRI signs of disease
activity (21).
Our results could support the potential significance
of UA in the modulation of the immune inflammatory
response in the CNS, as well as in the modulation of
those processes that could damage the BBB in
patients with MS. An animal model has shown that
UA molecules in serum could leak through a dam-
aged BBB (26). Our results may support this concept
since we found significant correlation between CSF
and serum UA concentrations in MS patients, but not
in controls. Additionally, we have shown significant
correlation between the CSF/serum albumin quotient,
a marker for disruption of the BBB (35), and CSF UA
concentrations in MS patients, but not in controls.
Disruption of the BBB is one of the key events in the
immunoinflammatory processes in MS (36). There-
fore, we could assume that CSF UA concentrations
depend partly on serum UA concentrations in patients
with a damaged BBB, and partly on the balance
between production and consumption within the
CNS. This could partially explain the absence of a sta-
tistical significance in the CSF UA concentrations
between patients with active and inactive MS in our
study. However, the number of patients included in
our study was rather small. We assume that statisti-
cally significant results could have been obtained in
a larger group of MS patients.
The pathogenetic role of UA in MS also is support-
ed by data showing the significant increase in serum
UA concentrations in patients receiving interferon-b
or glatiramer-acetate (37, 38), which have been shown
to reduce disease activity in MS (39). In addition, the
administration of high-dose methylprednisolone for
the treatment of MS relapse resulted in an increase
in serum UA concentrations in the study by Toncev
et al. (40).
The first steps toward the use of UA as a therapeu-
tic agent in EAE were done by Hooper et al. who
showed that treatment with UA inhibited the onset of
acute EAE in mice (41). Additionally, treatment with
UA was shown to promote long-term survival if treat-
ment was begun after the onset of EAE symptoms
(17). In addition, it also prevented disruption of the
blood/CNS barrier and the invasion of inflammatory
cells into the CNS in animals with EAE (18). In
humans, oral administration of UA did not result in
significant increases in serum UA concentrations (42).
Thus, in a study by Spitsin et al. (43), administration
of inosine, the precursor of UA, stopped the progres-
sion of MS in all 11 patients who received the drug;
three patients showed some clinical improvement.
Results of a phase II, double-blind, placebo-controlled
study with the use of inosine in 30 RRMS and SPMS
patients have not yet been published (http://clinical-
trials.gov/ct/show/NCT00067327). However, prelimi-
nary results indicate that manipulation of serum/CSF
UA concentrations could hold promise in MS (24).
Our results further support the significance of UA
in the pathogenesis of MS. Lowered serum UA con-
centrations in MS patients might be due to both intrin-
sically reduced antioxidant capacity and increased
consumption of UA in MS. CSF UA concentrations
may not be such a reliable marker of disease activity
in MS because CSF concentrations are dependent on
both leak of UA molecules into CSF from serum
through the damaged BBB and the balance between
consumption and production of UA within the CNS.
However, our results may support the idea that treat-
ment with UA precursors in patients with MS could
have potential benefits for both stable and active dis-
ease. This may reduce the likelihood of disease re-
activation and diminish the level of existing disease
activity. Clinical studies with greater numbers of MS
patients are necessary.
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